SLC5A2 and anemia: Given the increased cardiovascular risk associated with ESA therapy with or HIF-PHI inhibitor [73], and considering the high prevalence and associated mortality risk of functional iron deficiency [74], SGLT2 inhibitors could become an attractive alternative in the management of anemia in the dialysis population.